Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open, single-center, phase Ⅱ study to assess the efficacy and safety
of alternating Icotinib and chemotherapy for advanced non-small cell lung cancer with EGFR
mutation.